GLP-1 receptor agonists: A novel pharmacotherapy for binge eating (Binge eating disorder and bulimia nervosa)? A systematic review

IF 4.2 Q1 ENDOCRINOLOGY & METABOLISM Journal of Clinical and Translational Endocrinology Pub Date : 2024-03-01 DOI:10.1016/j.jcte.2024.100333

Laurence Aoun , Shaza Almardini , Fares Saliba , Fadi Haddadin , Omar Mourad , Jennifer Jdaidani , Zeina Morcos , Ibrahim Al Saidi , Elie Bou Sanayeh , Saliba Saliba , Michel Almardini , Julie Zaidan

{"title":"GLP-1 receptor agonists: A novel pharmacotherapy for binge eating (Binge eating disorder and bulimia nervosa)? A systematic review","authors":"Laurence Aoun , Shaza Almardini , Fares Saliba , Fadi Haddadin , Omar Mourad , Jennifer Jdaidani , Zeina Morcos , Ibrahim Al Saidi , Elie Bou Sanayeh , Saliba Saliba , Michel Almardini , Julie Zaidan","doi":"10.1016/j.jcte.2024.100333","DOIUrl":null,"url":null,"abstract":"<div><h3>Objective</h3><p>Systematically review evidence on using GLP-1RAs for reducing BEB in BED and BN.</p></div><div><h3>Methods</h3><p>Comprehensive literature search (PubMed and Google Scholar) conducted for studies evaluating GLP-1Ras for BEB. Extracted data on study characteristics, efficacy, and safety.</p></div><div><h3>Results</h3><p>Studies show that GLP-1RAs (liraglutide and dulaglutide) reduce BE frequency and comorbidities in addition to favorable psychiatric side effect profile compared to current options. However, large-scale, blinded placebo-controlled trials are lacking.</p></div><div><h3>Conclusion</h3><p>Early findings suggest promising effects of GLP-1RAs on BEB. However, rigorous clinical trials are needed to firmly establish efficacy, dosing, safety, and comparative effectiveness before considering GLP-1RAs a viable novel approach.</p></div>","PeriodicalId":46328,"journal":{"name":"Journal of Clinical and Translational Endocrinology","volume":null,"pages":null},"PeriodicalIF":4.2000,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2214623724000048/pdfft?md5=c4acfc67aff009fa931f433ff8458828&pid=1-s2.0-S2214623724000048-main.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Clinical and Translational Endocrinology","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2214623724000048","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}

引用次数: 0

Abstract

Objective

Systematically review evidence on using GLP-1RAs for reducing BEB in BED and BN.

Methods

Comprehensive literature search (PubMed and Google Scholar) conducted for studies evaluating GLP-1Ras for BEB. Extracted data on study characteristics, efficacy, and safety.

Results

Studies show that GLP-1RAs (liraglutide and dulaglutide) reduce BE frequency and comorbidities in addition to favorable psychiatric side effect profile compared to current options. However, large-scale, blinded placebo-controlled trials are lacking.

Conclusion

Early findings suggest promising effects of GLP-1RAs on BEB. However, rigorous clinical trials are needed to firmly establish efficacy, dosing, safety, and comparative effectiveness before considering GLP-1RAs a viable novel approach.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

GLP-1 受体激动剂：治疗暴食症（暴食症和贪食症）的新型药物疗法？系统综述

目的系统回顾使用 GLP-1RAs 减少 BED 和 BN 中 BEB 的证据。方法对评估 GLP-1Ras 治疗 BEB 的研究进行全面文献检索（PubMed 和 Google Scholar）。结果研究表明，GLP-1RAs（利拉鲁肽和度拉鲁肽）与目前的选择相比，除了具有良好的精神副作用外，还能减少 BEB 的频率和合并症。结论早期研究结果表明，GLP-1RA 对 BEB 具有良好的疗效。然而，在将 GLP-1RAs 视为一种可行的新方法之前，还需要进行严格的临床试验，以牢固确立其疗效、剂量、安全性和比较有效性。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊